Funding · Healthcare & Life Sciences

Immuneel raises ₹100 Cr in Series B

What they do

Immuneel Therapeutics develops cell and gene therapies for cancer

It raised over ₹100 Cr in Series B from Singularity AMC, Rainmatter, and existing investors

Funds will scale manufacturing, advance pipeline, and expand into Asia Pacific and Middle East

Immuneel Therapeutics raised over ₹100 Cr in a Series B funding round.
New investors Singularity AMC and Rainmatter by Zerodha participated.
Existing investors Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital also invested.
The company will use the funds to scale GMP manufacturing capacity.
It will also advance next-gen cell and gene therapy pipeline.
A significant portion will go toward commercialisation of Qartemi.
Immuneel plans to expand into Asia Pacific and Middle East markets.

India's gene therapy sector is growing with startups like Cellogen and Oncare raising funds.
China has hundreds of gene therapy companies, while India's biotech boom is recent.
Government funding and evolving investor/regulatory ecosystem are driving momentum.
CEO cautions long-term success requires manufacturing, supply chains, and GTM strategies beyond science.

Immuneel commercialised Qartemi, a CAR-T therapy for Non-Hodgkin Lymphoma.
CAR-T therapy modifies a patient's own immune cells to attack cancer.
Non-Hodgkin Lymphoma is a blood cancer of the lymphatic system.
The company currently treats lymphoma patients in India; leukemia treatment to start soon.
Solid tumor programs are in research, not yet in clinic.
It operates India's first internationally benchmarked CAR-T platform.
Over 100 patients have been treated since commercial launch in late 2024.
Immuneel aims to offer therapy at less than 10% of Western cost of $400,000–$500,000 per patient.

Singularity AMC (new investor) — An asset management company.
Rainmatter by Zerodha (new investor) — An investment arm of Zerodha.
Kiran Mazumdar-Shaw (existing investor) — Co-founder of Immuneel Therapeutics and a prominent biotech entrepreneur.
Eight Roads Ventures (existing investor) — A venture capital firm.
F-Prime Capital (existing investor) — A venture capital firm.

Product: CAR-T cell therapy and lentiviral vector manufacturing for blood cancer
Customers: Cancer patients in India and Asia Pacific
How it makes money: Direct therapy delivery and manufacturing services
What sets it apart: GMP-certified manufacturing with partnerships for clinical validation
Operations: Operates GMP manufacturing facilities in Bengaluru